These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 18398378

  • 1. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
    Utman SA, Dhillon B.
    Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
    [No Abstract] [Full Text] [Related]

  • 2. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
    Falkenstein IA, Cheng L, Freeman WR.
    Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
    [Abstract] [Full Text] [Related]

  • 3. Paracentesis before intravitreal injection of bevacizumab.
    Tsui YP, Chiang CC, Tsai YY.
    Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
    [No Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
    Kernt M, Neubauer AS, Kampik A.
    Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 6. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
    Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J.
    Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP, Haji SA, Frenkel RE.
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [Abstract] [Full Text] [Related]

  • 9. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
    Lee K, Yang H, Lim H, Lew HM.
    Retina; 2009 Dec; 29(10):1409-17. PubMed ID: 19816242
    [Abstract] [Full Text] [Related]

  • 10. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Dec; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 11. The effects of intravitreal ophthalmic medications on intraocular pressure.
    Wu H, Chen TC.
    Semin Ophthalmol; 2009 Dec; 24(2):100-5. PubMed ID: 19373694
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB, Sjølie AK, Møller F.
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [Abstract] [Full Text] [Related]

  • 13. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
    Ronan SM, Yoganathan P, Chien FY, Corcóstegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, López M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN.
    Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab.
    Lucas RS, McKee HD, Lee LR.
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection.
    Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG.
    Retina; 2010 Oct; 30(9):1432-40. PubMed ID: 20559156
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
    Chen CY, Wong TY, Heriot WJ.
    Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
    [Abstract] [Full Text] [Related]

  • 17. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA, Gorin MB.
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [Abstract] [Full Text] [Related]

  • 18. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.
    Ophthalmologica; 2009 Jun; 223(6):370-5. PubMed ID: 19590252
    [Abstract] [Full Text] [Related]

  • 19. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
    Spaide RF.
    Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
    [No Abstract] [Full Text] [Related]

  • 20. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F.
    Klin Oczna; 2010 Jul; 112(7-9):213-6. PubMed ID: 21121123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.